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Background
Many prognostic markers have been identified in chronic lymphocytic leukemia, but there
have been few opportunities to assess their relative importance in a large randomized trial. The
aim of this study was to determine which of the available markers independently predicted
outcome in patients requiring treatment and to use these to define new risk groups.
Design and Methods
A broad panel of clinical and laboratory markers, measured at randomization in patients enter-
ing the LRF CLL4 trial, was assessed with respect to treatment response, progression-free and
overall survival, at a median follow-up of 68 months.  
Results
Using the factors identified as independent predictors for progression-free survival, patients
were subdivided into three risk groups: 6% had poor risk with known TP53 loss of greater than
10%; 72% had an intermediate risk without TP53 loss (≤10%) and with at least one of: unmu-
tated IGHV genes and/or IGHV3-21 usage, 11q deletion, β-2 microglobulin greater than 4
mg/L; 22% had a good risk (with none of the above and mutated IGHV genes). The 5-year pro-
gression-free survival rates for these three groups were 0%, 12% and 34%, respectively, and
the corresponding 5-year overall survival rates were 9%, 53% and 79% (both P<0.00005 inde-
pendent of treatment allocation). In the intermediate risk group 250 patients, with data for all
three risk factors, were further subdivided into intermediate-low (one risk factor) or intermedi-
ate-high (2 or 3 risk factors). The 5-year progression-free survival rates were 18% and 7%
(P=0.0001) and the 5-year overall survival rates were 68% and 40% (P<0.00005), respectively. 
Conclusions
This study demonstrates the role of biomarkers in prognosis and shows that, in patients requir-
ing treatment, disease stage may no longer be an independent predictor of outcome. If validat-
ed independently, the risk groups defined here may inform the design of future trials in chronic
lymphocytic leukemia. 
(Clinicaltrials.gov identifier: NCT00004218; controlled-trials.com identifier ISRCTN58585610).
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progression-free survival, overall survival.
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Introduction
Considerable effort has been made to identify clinical
and laboratory factors that predict the natural history and
response to therapy of patients with chronic lymphocytic
leukemia (CLL). Early studies highlighted the importance
of disease stage and factors such as lymphadenopathy,
hepatosplenomegaly, anemia, thrombocytopenia, lym-
phocyte count, the pattern of bone marrow infiltration
and serum markers, all of which at least in part reflect
tumor burden.1 More recently, attention has focused on
both intrinsic and acquired features of the leukemic clone
which are independent of tumor burden. These biomark-
ers include IGHV gene mutational status and usage, CD38
and ZAP-70 expression and genomic abnormalities.2-8
Many of the published data derive from retrospective
analyses of patients studied from presentation to first
treatment and evaluate the role of prognostic factors as
markers of disease progression. Information on the value
of biomarkers, other than TP53 loss, in predicting out-
come in patients with a clinical indication for treatment is
more limited. In particular there are few published data
from prospective studies evaluating the role of prognostic
markers, measured at trial entry, in patients entered into
randomized clinical trials.9
The LRF CLL4 trial randomized 777 previously untreat-
ed patients with Binet stage progressive A, B or C disease
between January 1999 and October 2004 to receive either
chlorambucil, fludarabine or fludarabine and cyclophos-
phamide.10 This report, with a median follow-up of 68
months, represents the most comprehensive report pub-
lished to date on prognostic markers in CLL, measured at
the time of randomization into a large trial.
Design and Methods
Full details of the design, conduct and outcome of the LRF CLL4
trial have been published.10 All patients provided written informed
consent. The trial was approved by the UK South Thames
Multicentre Research Ethics Committee [MREC (1) 98/101] and
followed UK Medical Research Council guidelines for good clini-
cal practice.  
Laboratory markers
The non-clinical prognostic factors were measured on blood
samples taken at the time of trial entry. Fluorescence in situ
hybridization (FISH), mutational analysis of immunoglobulin vari-
able region genes (IGHV), and evaluation of CD38 and ZAP-70
expression were performed centrally. Serum lactate dehydroge-
nase  and beta-2 microglobulin (β-2M) were assayed at referring
hospitals and absolute values were reported. 
FISH was performed using commercially available probes
according to the manufacturers' instructions; the panel used (Vysis
from Abbott Laboratories, Berkshire, UK) comprised TP53
(17p13.1); D12Z3 (centromere12); D13S25 (13q14.3); either 11q23
or, later in the trial, ATM (11q22.3); and 6q21 (courtesy of Dr S
Stilgenbauer). At least 200 cells were examined for each probe in
all cases. The cut-off points for defining loss were greater than 5%
for 11q, 13q14 and 6q21, and greater than 3% for trisomy 12. In
view of the clinical importance of identifying patients with a TP53
abnormality, all cases originally found to have between 5% and
30% TP53 loss were reviewed independently by three to five
experienced cytogeneticists at the Royal Marsden and
Bournemouth hospitals. The selected cut off defining TP53 loss,
based on the mean of the results obtained from this review, was
10%, as discussed in more detail below. 
IGHV genes were sequenced from either cDNA or gDNA.
cDNA was synthesized by reverse transcription according to the
manufacturer’s protocol (Promega). cDNA was amplified as previ-
ously described.11
Sequences were aligned to current databases (V-BASE and
IMGT). IGHV gene stereotypes were classified according to the
criteria used by Stamatopoulos et al.12 CD38 expression was meas-
ured by flow cytometry using fresh samples stained with CD5-
FITC (BD Biosciences), CD38-PE (clone HB-7, BD Biosciences),
and CD19-TC (Caltag, Burlingame, CA, USA), as described by
Morilla et al.13 The choice of cut-off for both IGHV mutation and
CD38 positivity is described in the results section. ZAP-70 expres-
sion was measured by flow cytometry using samples frozen in
dimethylsulfoxide, as previously described.7 The previously vali-
dated7 cut-off of 10% was used to define ZAP-70 positivity, based
on correlations with IGHV gene mutational status, ZAP-70 mRNA
expression and clinical outcome.
Statistical analysis
Group-wise comparisons of clinical, laboratory and genetic data
were performed using the Kruskal-Wallis test or the χ2 test, as
appropriate. Overall survival was calculated from randomization
to death from any cause. Progression-free survival was calculated
from randomization to initial non-response, progression, or death
from any cause. Survival curves were constructed by the Kaplan-
Meier method and compared using the log-rank test. Multivariate
analyses of variables significant in the univariate log-rank tests
were performed by means of the Cox proportional hazards model
using step-wise forward selection. Treatment allocation was
included as a covariate in all multivariate models. Data on β-2M
and the biomarkers were not available for all patients and, since
some variables were missing for different sets of patients, the
numbers available for some multivariate analyses were reduced,
so caution is required in their interpretation. Odds-ratio plots
show the relative effect of prognostic markers within treatment
groups with tests for heterogeneity to indicate any evidence of a
different effect between treatments. The follow-up was to 31st
October 2008, with a median follow-up for survivors of 68
months (range, 48 months – 117 months). Statistical analyses were
conducted with SAS version 9.1 (SAS Institute Inc, Cary, NC,
USA) and in-house programs. All P values given are two-sided.
Results
The patients’ characteristics and the number of patients
in whom each prognostic marker was measured are
shown in Table 1. There was no significant difference in
the age, gender, Binet stage, treatment allocation, progres-
sion-free survival or overall survival among cases in whom
biomarkers were tested compared to the remaining
patients. Additionally there was no imbalance in any of
the patients’ characteristics by treatment arm (data not
shown).
Clinical factors
In univariate analysis male gender, Binet stage C or Rai
stage 3 or 4 disease, lower hemoglobin, higher lympho-
cyte count and lower platelet count were all associated
with poorer response to treatment. Male gender (P=0.03),
lower hemoglobin (P=0.001), higher lactate dehydroge-
nase concentration (P=0.008) and higher lymphocyte
count (P<0.00005) were associated with shorter progres-
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sion-free survival, while male gender (P=0.02), advanced
stage (P=0.0002), increasing age (P<0.00005) and lower
hemoglobin (P<0.00005) correlated with shorter overall
survival (Online Supplementary Table S1).  
Beta-2 microglobulin
β-2M levels were significantly higher in older patients
(P<0.0001), in males (P=0.001), in stage C compared to
stage B (P=0.0006) and in stage B compared to progressive
stage A disease (P<0.0001). Using the cut off of 4 mg/L,
there were significant associations between β-2M levels
and unmutated IGHV genes and high CD38 expression,
and a borderline association with the absence of a 13q
deletion. Higher β-2M levels were significantly associated
with poorer response to treatment (P=0.0001), shorter
progression-free survival (P=0.0001) and shorter overall
survival (P<0.00005) (Online Supplementary Table S2).
Fluorescence in situ hybridization analysis
A greater than 10% loss of TP53 was detected in 33
cases (5.8%), of whom 31 had greater than 20% loss. The
outcome of the two cases with 10-20% loss was compa-
rable to that of the cases with greater than 20% loss and
the outcome of those with 5-10% loss was similar to that
of patients with less than 5% loss. Deletion of 13q, 11q,
6q and trisomy 12 was found in 344 (59%), 116 (20%), 33
(8%) and 88 (15%) of cases, respectively. Eighty-three
patients (15%) had no FISH abnormality. Four patients
had greater than 10% TP53 loss in addition to greater than
5% 11q loss.
Dohner’s hierarchical model4 was used to examine the
influence of genomic abnormalities on response rate, pro-
gression-free survival and overall survival (Figure 1A and
Online Supplementary Table S2). In those with greater than
10% TP53 loss the overall response rate was low at 29%
(compared with 82% in non-TP53 cases, P<0.0001), with
only 6% patients achieving a complete or nodular partial
response. Outcome overall was very poor indicating that
these patients were not salvaged with subsequent thera-
pies. Five patients had TP53 loss in the range of 5-9.99%
and their outcome was comparable to that of patients
with less than 5% loss. Excluding the patients with TP53
loss, 11q loss was associated with a lower overall response
rate (72% versus 84%, P=0.005), shorter progression-free
survival (P<0.00005) and shorter overall survival
(P=0.0004) compared to those in patients without 11q
loss. Deletion of 13q as a sole abnormality was found in
224 patients and was associated with superior progres-
sion-free survival (P=0.0003) and overall survival
(P<0.00005), but no difference in overall response rate
(84% versus 79%, P=0.2), compared to these outcomes in
patients with other abnormalities (excluding TP53 loss) or
normal FISH (n=284). Trisomy 12 and 6q loss had no influ-
ence on response or progression-free survival.
Prognostic stratification in CLL
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Table 1. Patients’ characteristics.
Patients’ characteristic / prognostic marker                            Total
Treatment allocation                                   Chlorambucil                387 (50%)
                                                                            Fludarabine                  194 (25%)
                                                                                    FC                          196 (25%)
Sex                                                                          Male                        573 (74%)
                                                                                 Female                      204 (26%)
Age (years)                                                            <60                         255 (33%)
                                                                                   60-69                        288 (37%)
                                                                                    ≥70                         234 (30%)
                                                                        Median (range)              64 (35-86)
Binet stage                                                     A-progressive                191 (25%)
                                                                                     B                            352 (45%)
                                                                                     C                            234 (30%)
Rai stage                                                                     0                              32 (4%)
                                                                                       I                            188 (24%)
                                                                                      II                            248 (32%)
                                                                                     III                           162 (21%)
                                                                                      IV                           147 (19%)
Hemoglobin (g/dL)                                                  n                                  777
                                                                        Median (range)          12.3 (3.8-19.2)
Absolute lymphocyte count (x109/L)                   n                                  751
                                                                         Median (range)              78 (1-570)
                                                                          Not available                        26
Platelets count (x109/L)                                          n                                  777
                                                                        Median (range)             151 (2-684)
Lactate dehydrogenase (U/L)                               n                                  700
                                                                         Median (range)            417 (4-1953)
                                                                          Not available                        77
Beta-2 microglobulin (mg/L)                                n                                  557
                                                                        Median (range)             3.7 (0-29.4)
                                                                          Not available                       220
FISH (Dohner’s hierarchical model)*  TP53 del (10%)                 33 (6%)
                                                                              11q- (5%)                    112 (21%)
                                                                             tris12 (3%)                   69 (13%)
                                                                               6q- (5%)                       20 (4%)
                                                                                 normal                       83 (15%)
                                                                              13q- (5%)                    224 (41%)
                                                                          Not available                       236
IGHV gene mutation (98% cut off)               Mutated                     206 (39%)
                                                                            Unmutated                  327 (61%)
                                                                          Not available                       244
CD38 expression                                                    ≤7%                         201 (38%)
                                                                                   >7%                         334 (62%)
                                                                          Not available                       242
ZAP-70 expression                                               ≤10%                        242 (51%)
                                                                                 >10%                       236 (49%)
                                                                          Not available                       299
Data are number (%), median (range) or number not available. *FISH tested on n=579
patients for all abnormalities, except TP53 deletion (n=571) and deletion of 6q (n=390).
FC: fludarabine + cyclophosphamide. 
Table 2. Multivariate analysis of prognostic factors independently asso-
ciated with progression-free and overall survival (in patients without
TP53 loss).
Variable Hazard Ratio 95% CI P value
Progression-free survival
IGHV unmutated / V3-21 2.01 1.53-2.65 <0.0001
Deletion of 11q 1.66 1.25-2.22 0.0006
Beta-2 microglobulin >4 mg/L 1.08 1.02-1.15 0.007
Treatment: 
Chlorambucil 1.00 <0.0001
Fludarabine 0.92 0.69-1.23
Fludarabine+cyclophosphamide 0.42 0.31-0.57
Overall survival
Age (years) 1.06 1.04-1.08 <0.0001
Beta-2 microglobulin >4 mg/L 1.10 1.03-1.17 0.005
IGHV unmutated / V3-21 2.16 1.45-3.21 0.0001
Treatment: 
Chlorambucil 1.00 0.9
Fludarabine 0.99 0.66-1.47
Fludarabine+cyclophosphamide 0.93 0.64-1.35
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IGHV gene analysis
Regardless of whether a 98% or 97% cut-off was used,
there were comparable and significant differences in
response rate (P=0.01 and P=0.009, respectively) and in
progression-free and overall survival between mutated
and unmutated cases (P<0.00005 for both cut-offs, for
both outcome measures) (Online Supplementary Table S2).
A 98% cut-off was chosen for all further analyses given its
widespread use in the literature. Forty patients utilized the
IGHV3-21 gene of whom 35 had highly homologous
CDR3.  There were significant differences in progression-
free survival (P=0.008) and overall survival (P=0.001)
between IGHV3-21 cases and mutated cases without
IGHV3-21 gene usage (Figure 1B and Online Supplementary
Table S2). There were significant associations between
unmutated IGHV genes and male gender, 11q, no loss of
13q, trisomy 12 and increased expression of CD38 and
ZAP-70. Whereas some previous studies found that TP53
loss was virtually confined to cases with unmutated IGHV
genes, seven (24%) of our cases with greater than 10%
TP53 loss had mutated IGHV genes (Online Supplementary
Table S3).
CD38 and Zap-70 expression
Since various cut-offs for CD38 have been reported in
the literature, we evaluated the prognostic significances of
7%, 20% and 30% cut-offs. There was no correlation
between CD38 expression and response rate regardless of
the cut-off used.  High CD38 expression was associated
with shorter progression-free and overall survival (Online
Supplementary Table S2). There was no difference in either
outcome measure between those with 8-20% and those
with 21-30% CD38 expression, or between the 21-30%
and greater than 30% groups, suggesting that a 7% cut-off
is most appropriate. Patients with 7% or less expression
had a significantly better outcome (Figure 1C). ZAP-70
positive patients had a significantly poorer overall
response rate (P=0.008) and significantly shorter progres-
sion-free survival (P<0.00005), but an only borderline
worse overall survival (P=0.07). 
Multivariate analysis and risk groups
The independent prognostic value of all clinical and lab-
oratory factors found to be significant in univariate analy-
ses (Online Supplementary Tables S1 and S2) was assessed
together, using proportional hazard regression models for
progression-free survival and overall survival. In the initial
multivariate analysis, deletion of TP53 conferred a
markedly inferior prognosis, independently of any other
factors. Therefore, in order to determine which factors
had independent prognostic value in patients without
TP53 deletion, the 33 patients with greater than 10% TP53
deletion were excluded from all further multivariate analy-
ses. 
β-2M (P=0.007), 11q deletion (P=0.0006) and IGHV
mutational status and/or IGHV3-21 usage (P<0.0001), as
well as the treatment allocation (P<0.0001), were identi-
fied as independent predictors for progression-free sur-
vival (Table 2).  ZAP-70 and CD38 expression were only
retained as independent predictors for progression-free
survival in the absence of information on IGHVmutation-
al status. The most important independent prognostic fac-
tors for overall survival were β-2M (P=0.005), IGHVmuta-
tional status and/or IGHV3-21 usage (P=0.0001) and age
(P<0.0001) (Table 2). There was a suggestion that both
CD38 expression and deletion of 11q also had borderline
independent effects on overall survival, however, it was
not possible to ascertain this with certainty due to missing
data and decreasing numbers of patients in the models.
None of the clinical variables associated with shorter pro-
gression-free survival or overall survival in the univariate
analyses (Online Supplementary Table S1) was retained as
an independent predictor in the multivariate analysis,
other than treatment allocation (progression-free survival)
D. Oscier et al.
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Figure 1. Factors associated with progression-free survival. (A)
Progression-free survival by Dohner’s hierarchical group. (B)
Progression-free survival by IGHV mutational status and/or IGHV3-
21 use.  (C) Progression-free survival by CD38 expression.
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and age (overall survival) (Table 2).
Using the factors identified as independent predictors
for progression-free survival, it was possible to sub-divide
all CLL4 patients into three risk groups with differing pro-
gression-free survival rates as follows: (i) a group of 33
(6%) patients was considered at poor risk based on known
TP53 loss of greater than 10%; (ii) a further group of 374
(72%) patients was at intermediate risk defined by TP53
loss of 10% or less and the presence of at least one of the
following: unmutated IGHV genes and/or IGHV3-21
usage, 11q deletion or a β-2M level of  >4 mg/L; and (iii)
112 (22%) patients with none of the above intermediate
risk factors, TP53 loss of 10% or less and mutated IGHV
genes, were assigned to a good risk category. The 5-year
progression-free survival rate (with 95% confidence inter-
val) (Figure 2A) was 0% for the poor risk group, 12% (9-
16%) for the intermediate risk group and 34% (25-43%)
for the good risk group. Two hundred and fifty-eight
patients from the trial were not assigned to a risk group
because of missing genetic information. The 5-year pro-
gression-free survival for this group was 19% (14-24%).
These risk groups also predicted for overall survival and
response to treatment. For overall survival (Figure 2B) the
risk groups separated patients with 5-year overall survival
rates of 9% (0-19%), 53% (47-58%) and 79% (71-87%),
respectively (P<0.00005). Within each Binet stage the risk
groups defined substantially different survival rates
(12.5%, 56%, 85% in stage A, 17%, 55%, 77% in stage B,
0%, 44%, 72% in stage C). The 5-year overall survival rate
of the patients not assigned to a risk group was 61% (55-
67%). In terms of response rates, 89 (87%) of patients in
the good risk category achieved a response (complete,
nodular partial or partial response) compared with 283
(79%) in the intermediate risk and 9 (29%) in the poor risk
(P<0.0001).  There was also a highly significant associa-
tion (P<0.0001) with good response to treatment. 
We investigated the effect on outcome of the number of
risk factors present in the 250 patients in the intermediate
risk group who had data for all three factors which define
the intermediate risk group: 13.2% of patients had all
three of these poor risk factors, 40.8% had two, and
46.0% had one. Increasing numbers of poor risk features
significantly affected both progression-free survival and
overall survival. The 5-year progression-free survival rate
was 18% (11-25%) for patients with one risk factor, 8%
(2-13%) for those with two and 6% (0-14%) for those
with three risk factors. The corresponding 5-year overall
survival rates were 68% (59-77%), 42% (32-52%) and
30% (13-47%).
In view of the small number of patients with three risk
factors and their similar outcome to those with two risk
factors, cases with two or three risk factors were com-
Prognostic stratification in CLL
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Figure 2. Progression-free survival and overall survival by risk
group. (A) Progression-free survival.  Poor risk: >10% TP53 loss.
Intermediate risk: ≤10% TP53 loss and at least one of: unmutated
IGHV genes, IGHV3-21 usage, beta-2 microglobulin >4 mg/L, 11q
loss >5%.  Good risk: ≤10% TP53 loss, none of the intermediate risk
factors and mutated IGHV genes.  (B) Overall survival.
Figure 3. Progression-free survival and overall survival in the inter-
mediate risk group by number of adverse risk factors (among 250
patients for whom complete information was available). (A)
Progression-free survival. (B) Overall survival.
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bined, comprising 54% of patients in the intermediate
group, with a 5-year progression-free survival of 7% (3-
11%) and overall survival of 40% (31-48%) (Figure 3A-B).
This analysis was not integrated with Figure 2, as it was
based on a subset of patients only: those with complete
data for all the factors considered.
Effect of prognostic markers within treatment 
allocation
There was no significant difference in the relative effect
of 11q deletion, IGHV mutational status, IGHV3-21 use
and levels of β-2M between treatment groups for either
progression-free survival or overall survival, and conse-
quently risk groups were relevant for all treatments (Figure
4).  Overall response rates, as well as progression-free and
overall survival were consistently best in the good risk
group and worst in the poor risk group, across all three
treatment groups (Online Supplementary Table S4).
Discussion
The LRF CLL4 trial evaluated the prognostic signifi-
cance of age, gender, risk factors reflecting tumor burden,
and biomarkers for prediction of three end-points: treat-
ment response, progression-free survival and overall sur-
vival. This was a large study of patients randomized to
receive first-line treatment with chlorambucil, fludara-
bine, or fludarabine with cyclophosphamide, analyzed at
a median follow-up of 68 months.10 Multivariate analysis
of factors found to be significant in univariate analyses
showed that greater than 10% TP53 loss, a β-2M level of
greater than 4 mg/L, 11q loss, unmutated IGHV genes
and/or use of the IGHV3-21 gene, and treatment alloca-
tion were independent predictors of progression-free sur-
vival. Greater than 10% TP53 loss, age, β-2M level and
IGHV mutational status and/or IGHV3-21 usage were
independent predictors of overall survival. It should be
noted that disease stage was not an independent predic-
tor of either progression-free survival or overall survival.
As in previous retrospective studies, TP53 loss was the
most significant factor predictive of poor response rate
and short progression-free and overall survival.9,11,14,15 The
choice of a 10% cut-off to define TP53 loss was based on
FISH results obtained by experienced cytogeneticists
from two centers and correlated well with clinical out-
come. However it is possible that other factors such as
the presence of TP53 mutation on the remaining allele or
the degree of genomic complexity may also influence out-
come in patients with comparable levels of TP53 loss.
Recent studies have shown that TP53 mutation in the
absence of TP53 loss is also associated with poor risk dis-
ease.16,17 Patients entered into the UKCLL4 trial were
screened for the presence of a TP53 mutation and these
results will be reported separately.18
A second important finding from this study is the inde-
pendent prognostic significance of β-2M levels. Patients
with a creatinine clearance of less than 30 mL/min were
excluded from this trial so it is unlikely that high β-2M
levels reflected poor renal function.19 Previous studies
have shown that β-2M is a predictor of progressive dis-
ease, progression-free survival and overall survival.20-22
However this is the first study to show that this simple,
readily available and inexpensive assay retains prognostic
significance even in models that include a comprehensive
range of demographic and biological risk factors. 
In keeping with previous retrospective studies11,14 and
the US Intergroup phase III E2997 trial,9 deletion of 11q
using a FISH probe encompassing the ATM gene and a
cut-off of 5% correlated with poor response and shorter
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Figure 4. Effect of risk
group on progression-free
survival and overall sur-
vival within the random-
ized treatment arms.  The
squares and lines show
the estimated odds ratio
and their 95% confidence
interval (95% CI). The size
of each square is propor-
tional to the amount of
information in the sub-
group. Overall estimates
are shown by a diamond,
with the width represent-
ing the 95% CI. O-E:
observed minus expected;
V: variance; NS=not signif-
icant.
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progression-free survival. The 11q deletion remained a
poor risk factor regardless of treatment allocation
although those cases receiving fludarabine and
cyclophosphamide had a significantly longer progression-
free survival than cases in the other two arms (Online
Supplementary Figure S1). There is some evidence that the
adverse effect of 11q loss might be overcome by the use
of chemo-immunotherapy including rituximab, highlight-
ing the fact that the predictive value of prognostic mark-
ers may sometimes be dependent on the type of treat-
ment received.23 However, this has not been demonstrat-
ed by comparisons of patients with or without 11q dele-
tion in large cohorts of patients with adequate follow-up
from first treatment and uncertainty remains. 
While the ability of IGHV gene mutational status to
predict progressive disease in early stage CLL is well doc-
umented, its value as an outcome measure in patients
with more advanced disease requiring treatment is less
clear.9,24,25 Grever et al.9 found that it had no effect on pro-
gression-free survival, while this study demonstrates that
IGHV gene mutational status using either a 98% or 97%
cut-off is an independent risk factor for both progression-
free survival and overall survival in patients requiring
treatment by conventional criteria. This disparity may
reflect differences in sample size, duration of follow-up
and methodology. Recent studies have highlighted the
prognostic importance of IGHV gene stereotypes, inde-
pendent of mutational status. The incidence of the
IGHV3-21 stereotype was 7.5%, comparable to that in
other Northern European populations and, as expected,
this stereotype was associated with a poorer outcome
than other mutated cases.5,26 The incidence of other
stereotypes, found in 37% of unmutated and 9% of
mutated cases (data not shown), was also comparable to
the incidence found in other recent studies.12,27 
Both high CD38 and ZAP-70 expression were associat-
ed with short progression-free survival in univariate
analysis. In view of the differing CD38 levels which best
predicted outcome in previous studies, we compared cut-
offs of 7%, 20% and 30% and found no significant differ-
ence in outcome for any value greater than 7%. This is
consistent with recent models suggesting that CD38
expression in circulating CLL lymphocytes may be tran-
sient and at least partly reflects recent exposure to the
microenvironment which supports leukemic prolifera-
tion.28-30 Neither ZAP-70 nor CD38 expression was a clear
independent poor risk factor in the CLL4 trial when
IGHV gene mutational status was included in the multi-
variate models.
Stratification of CLL patients requiring therapy into risk
groups has a number of potential benefits. It can inform
patients about their likely outcomes, partially explain dif-
ferences in outcome data among studies, provide an
opportunity to balance randomization by risk group in
future clinical trials, and, most importantly, influence the
choice of therapy. Accordingly we assigned patients to
one of three risk groups using the factors that were pre-
dictive of poor progression-free survival in multivariate
analysis, with 5-year progression-free survival rates of
0%, 12% and 34% for the poor, intermediate and good
risk groups and 5-year overall survival rates of 9%,  53%,
and 79%, respectively. A subset analysis of patients in the
intermediate risk group for whom data on all the inde-
pendent risk factors were available further divided this
group into those with either one risk factor (low interme-
diate) or two or three risk factors (high intermediate) with
differing progression-free and overall survival rates. The
poorer outcome of patients with more than one risk fac-
tor is also seen in stage A patients among whom those
with more than one adverse risk factor have a shorter
treatment-free survival.31-33
A number of important conclusions can be drawn from
this study. Firstly, the poor outcome of patients with 17p
loss treated with alkylator/purine analog therapy is con-
firmed, supporting the need to screen patients for a TP53
abnormality prior to initial therapy. Secondly, those
patients receiving fludarabine and cyclophosphamide had
a better outcome than those in the other treatment arms
independently of prognostic factors, supporting the use of
more intensive therapy in patients who are fit enough to
receive it, regardless of chronological age. Thirdly, IGHV
gene mutational status and/or IGHV3-21 usage, β-2M
levels and 11q loss identified risk groups with different
outcomes, regardless of the treatment allocation. More
frequently than not, prognostic factors remain valid, inde-
pendent of treatment. Nevertheless, we recognize that
this requires confirmation in other independent data sets,
particularly those in which patients are treated with
newer combination therapies, including monoclonal anti-
bodies. In addition, recent trials employing intensive
chemotherapy or chemo-immunotherapy regimens have
highlighted the prognostic importance of achieving a
state of no minimal residual disease. It will be important
to determine whether the incidence of negativity for min-
imal residual disease varies among the risk groups identi-
fied in this study or whether minimal residual disease sta-
tus is independent of biomarkers.
If confirmed, the significant improvement in overall
survival for patients in the good risk group who relapse
after initial treatment indicates that such patients respond
to second-line therapies and, by implication, may not be
acquiring poor risk genomic abnormalities. There is cur-
rent interest in consolidation therapy with alemtuzumab
for patients who have a good response to initial treatment
but remain positive for minimal residual disease. This
improves progression-free survival but may be associated
with morbidity and, very occasionally mortality. Further
studies will be necessary to determine whether the use of
consolidation or maintenance therapy following initial
treatment should be based on the presence of the adverse
risk factors identified in this trial. 
If validated by others in different settings, the risk
groups identified in this study could inform the design of
future trials and may represent a major shift of emphasis
in the prognosis for CLL patients.
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